Median ESKD-free survival time was 8.7 (95% CI 8.0–9.4) years for SMARCAL1 vs. 13.0 (95%CI 11.8–14.1) years for NPHS2 nephropathy (p = 0.013) (Fig 2). Here, SMARCAL1 is linked to Nephropathy.